Authors
Latest:
Relapsed/Refractory CLL: Key Takeaways and Ongoing ChallengesClosing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.
Latest:
Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.
Latest:
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRCThe FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
Latest:
Key Takeaways and Clinical Pearls on the Treatment of R/R MM in the Era of BispecificsThe panel concludes its discussion with key takeaways on the evolving treatment landscape for multiple myeloma.
Latest:
Unmet Needs and Future Perspectives in NSCLC TreatmentThe panelists close their discussion on non-small cell lung cancer by emphasizing the need for continued research, early screening, and collaboration with dermatologists to address the unmet needs and improve overall outcomes.
Latest:
Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsExperts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
Latest:
Sound Biologic Foundation May Support Metformin in Li-Fraumeni SyndromeThe ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Latest:
Decisional Capacity Determination in Patients With CancerExperts discuss the process of assessing decision-making capacity in patients with cancer.
Latest:
Expert Commentary on the product profile of Belzutifan for Renal Cell CarcinomaIn an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.
Latest:
Changing the Pancreatic Cancer Landscape Via Liquid BiopsyThe relatively inexpensive nature of liquid biopsy may allow for more frequent screening among individuals who are at risk of developing pancreatic cancer.
Latest:
Signaling Pathways in the Relapse of GlioblastomaJavier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.
Latest:
Which Larynx-Preservation Strategy Would Be Best for a Patient With Resectable, Locally Advanced, Hypopharynx Squamous Cell Carcinoma?A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician’s office. He received empirical treatment with oral antibiotics and experienced partial improvement. A couple of months later, he developed a left cervical mass with progressive growth. A head and neck CT scan revealed a hypopharyngeal tumor. Results of a tumor biopsy indicated an ulcerated, moderately differentiated squamous cell carcinoma (SCC) with lymphovascular invasion. The patient was sent to our institution for treatment.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Cancer Pain and Opioid Use DisorderInvestigators support individualized approaches and compassionate care to minimize nonmedical opioid use and opioid use disorder in patients with cancer pain.
Latest:
Lisa La on the Limitations of a Study Evaluating Diabetes in Patients with Multiple MyelomaThe clinical investigator and her colleagues sought to evaluate differences in baseline characteristics, treatment patterns, and survival outcomes in diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.
Latest:
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell CarcinomaIn this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
Latest:
Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a CarcinosarcomaOn this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.
Latest:
Reid Merryman, MD, on Potential Clinical Designs with MRD-Guidance for Patients with DLBCLExpert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.
Latest:
Expert Insight and Future Perspectives for Follicular LymphomaPanelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.
Latest:
Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRCThe panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.
Latest:
Managing Hematological Toxicities Associated with Bispecifics in MMExperts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.
Latest:
Cancer Network Faceoff: Conclusion of the Event and Presentation of AwardsConclusion of the discussion and award presentation.
Latest:
Cancer Network Faceoff: Conclusion of the Event and Presentation of AwardsConclusion of the discussion and award presentation.
Latest:
Addition of Sintilimab to Bevacizumab Biosimilar IBI305 and Chemo Boosts PFS vs Chemo in Advanced EGFR-Mutant NSCLCPatients with locally advanced or metastatic EGFR-mutant nonsquamous non–small cell lung cancer who progressed on an EGFR inhibitor may benefit from treatment with sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy vs chemotherapy alone.
